Literature DB >> 20181786

DHA may prevent age-related dementia.

Greg M Cole1, Sally A Frautschy.   

Abstract

The risk for dementia, a major contributor to incapacitation and institutionalization, rises rapidly as we age, doubling every 5 y after age 65. Tens of millions of new Alzheimer's disease (AD) and other dementia cases are projected as elderly populations increase around the world, creating a projected dementia epidemic for which most nations are not prepared. Thus, there is an urgent need for prevention approaches that are safe, effective, and affordable. This review addresses the potential of one promising candidate, the (n-3) fatty acid docosahexaenoic acid (DHA), which appears to slow pathogenesis of AD and possibly vascular dementia. DHA is pleiotropic, acting at multiple steps to reduce the production of the beta-amyloid peptide, widely believed to initiate AD. DHA moderates some of the kinases that hyperphosphorylate the tau-protein, a component of the neurofibrillary tangle. DHA may help suppress insulin/neurotrophic factor signaling deficits, neuroinflammation, and oxidative damage that contribute to synaptic loss and neuronal dysfunction in dementia. Finally, DHA increases brain levels of neuroprotective brain-derived neurotrophic factor and reduces the (n-6) fatty acid arachidonate and its prostaglandin metabolites that have been implicated in promoting AD. Clinical trials suggest that DHA or fish oil alone can slow early stages of progression, but these effects may be apolipoprotein E genotype specific, and larger trials with very early stages are required to prove efficacy. We advocate early intervention in a prodromal period with nutrigenomically defined subjects with an appropriately designed nutritional supplement, including DHA and antioxidants.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20181786      PMCID: PMC2838628          DOI: 10.3945/jn.109.113910

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  58 in total

Review 1.  The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease.

Authors:  Greg M Cole; Sally A Frautschy
Journal:  Exp Gerontol       Date:  2006-10-17       Impact factor: 4.032

2.  Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis.

Authors:  Leslie G Cleland; Gillian E Caughey; Michael J James; Susanna M Proudman
Journal:  J Rheumatol       Date:  2006-08-01       Impact factor: 4.666

3.  n-3 polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism.

Authors:  J S Rao; R N Ertley; H-J Lee; J C DeMar; J T Arnold; S I Rapoport; R P Bazinet
Journal:  Mol Psychiatry       Date:  2006-09-19       Impact factor: 15.992

Review 4.  NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies.

Authors:  Patrick L McGeer; Edith G McGeer
Journal:  Neurobiol Aging       Date:  2006-05-11       Impact factor: 4.673

5.  Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study.

Authors:  Ernst J Schaefer; Vanina Bongard; Alexa S Beiser; Stefania Lamon-Fava; Sander J Robins; Rhoda Au; Katherine L Tucker; David J Kyle; Peter W F Wilson; Philip A Wolf
Journal:  Arch Neurol       Date:  2006-11

6.  Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.

Authors:  M E Risner; A M Saunders; J F B Altman; G C Ormandy; S Craft; I M Foley; M E Zvartau-Hind; D A Hosford; A D Roses
Journal:  Pharmacogenomics J       Date:  2006-01-31       Impact factor: 3.550

Review 7.  Cardiovascular risk factors for Alzheimer's disease.

Authors:  Clive Rosendorff; Michal S Beeri; Jeremy M Silverman
Journal:  Am J Geriatr Cardiol       Date:  2007 May-Jun

Review 8.  Neuroprotective effects of curcumin.

Authors:  Greg M Cole; Bruce Teter; Sally A Frautschy
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

9.  Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels.

Authors:  Kim N Green; Hilda Martinez-Coria; Hasan Khashwji; Eileen B Hall; Karin A Yurko-Mauro; Lorie Ellis; Frank M LaFerla
Journal:  J Neurosci       Date:  2007-04-18       Impact factor: 6.167

10.  Dose escalation of a curcuminoid formulation.

Authors:  Christopher D Lao; Mack T Ruffin; Daniel Normolle; Dennis D Heath; Sandra I Murray; Joanne M Bailey; Martha E Boggs; James Crowell; Cheryl L Rock; Dean E Brenner
Journal:  BMC Complement Altern Med       Date:  2006-03-17       Impact factor: 3.659

View more
  35 in total

1.  A complex dietary supplement augments spatial learning, brain mass, and mitochondrial electron transport chain activity in aging mice.

Authors:  Vadim Aksenov; Jiangang Long; Jiankang Liu; Henry Szechtman; Parul Khanna; Sarthak Matravadia; C David Rollo
Journal:  Age (Dordr)       Date:  2011-11-27

Review 2.  Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: interaction with apolipoprotein E genotype.

Authors:  P Barberger-Gateau; C Samieri; C Féart; M Plourde
Journal:  Curr Alzheimer Res       Date:  2011-08       Impact factor: 3.498

3.  Red blood cell ω-3 fatty acid levels and markers of accelerated brain aging.

Authors:  Z S Tan; W S Harris; A S Beiser; R Au; J J Himali; S Debette; A Pikula; C Decarli; P A Wolf; R S Vasan; S J Robins; S Seshadri
Journal:  Neurology       Date:  2012-02-28       Impact factor: 9.910

4.  Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD).

Authors:  Walter J Lukiw
Journal:  Expert Opin Emerg Drugs       Date:  2012-03-23       Impact factor: 4.191

5.  Docosahexaenoic acid supplementation in age-related cognitive decline: a systematic review and meta-analysis.

Authors:  Rakesh Balachandar; Soundarya Soundararajan; Bhavani Shankara Bagepally
Journal:  Eur J Clin Pharmacol       Date:  2020-02-14       Impact factor: 2.953

Review 6.  Omega-3 essential fatty acids modulate initiation and progression of neurodegenerative disease.

Authors:  R Palacios-Pelaez; Walter J Lukiw; Nicolas G Bazan
Journal:  Mol Neurobiol       Date:  2010-05-14       Impact factor: 5.590

Review 7.  Why pleiotropic interventions are needed for Alzheimer's disease.

Authors:  Sally A Frautschy; Greg M Cole
Journal:  Mol Neurobiol       Date:  2010-05-02       Impact factor: 5.590

8.  A defect in Δ6 and Δ5 desaturases may be a factor in the initiation and progression of insulin resistance, the metabolic syndrome and ischemic heart disease in South Asians.

Authors:  Undurti N Das
Journal:  Lipids Health Dis       Date:  2010-11-09       Impact factor: 3.876

9.  Nutritional concerns, health and survival in old age.

Authors:  C P G M de Groot; W A van Staveren
Journal:  Biogerontology       Date:  2010-05-21       Impact factor: 4.277

10.  Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and Aβ pathology and modulates Aβ oligomerization.

Authors:  Edmond Teng; Karen Taylor; Tina Bilousova; David Weiland; Thaidan Pham; Xiaohong Zuo; Fusheng Yang; Ping-Ping Chen; Charles G Glabe; Alison Takacs; Dennis R Hoffman; Sally A Frautschy; Gregory M Cole
Journal:  Neurobiol Dis       Date:  2015-09-12       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.